Two-year DETOUR2 study results presented at VAM 2023

Sean Lyden

Endologix has announced the 24-month results of the DETOUR2 study, presented at VAM 2023, the annual meeting of the Society for Vascular Surgery (SVS), by one of the study’s principal investigators, Sean Lyden, MD,  chairman of vascular surgery at the Cleveland Clinic in Cleveland, Ohio.

Percutaneous transmural arterial bypass (PTAB) with the Detour system, recently received premarket approval Approval from the Food and Drug Administration (FDA). The system enables physicians to percutaneously bypass lesions in the superficial femoral artery, by using stents routed through the femoral vein to restore blood flow to the leg. The Detour system is comprised of the Endocross device and Torus stent grafts.

The DETOUR2 study enrolled 202 patients in the U.S. and Europe. The 24-month results from the study indicated that 96% of enrolled patients had chronic total occlusions, with a mean lesion length of 32.7cm. Technical success was achieved in 100% of treated patients and the primary safety endpoint was surpassed with a 30-day major adverse event (MAE) rate of 7%

The freedom from clinically driven target lesion revascularization (CD-TLR) at 24 months was 76.7%, and secondary patency was 82.3%. The freedom from symptomatic deep vein thrombosis (DVT) was 96.5%, and freedom from major lower limb amputation was 98.5% at 24 months.

“The two-year results from the DETOUR2 Study are encouraging and demonstrate PTAB using the Detour system offers good patency rates in long superficial femoral artery (SFA) lesions. As noted in the conclusion of the presentation, the two-year data mimics those of surgical bypass without the need for general anesthesia, long length of stay, and high risk of complications. We look forward to continuing to study the Detour system,” said Lyden.


Please enter your comment!
Please enter your name here